Polyunsaturated fatty acid metabolism modulation

Polyunsaturated fatty acid metabolism modulation refers broadly to interventions that alter the endogenous synthesis, modification, and breakdown of polyunsaturated fatty acids within cells. This includes targeting enzymatic steps catalyzed by desaturases (such as delta–5/desaturase [FADS1] and delta–6/desaturase [FADS2]), elongases (such as ELOVL5), synthases, transporters involved in uptake/export, and regulatory transcription factors influencing these processes. These metabolic activities are essential for maintaining membrane fluidity/composition; generating bioactive lipids that regulate inflammation/cell signaling; controlling gene expression through nuclear receptors; influencing cell fate decisions including susceptibility to ferroptosis-mediated cell death; and contributing significantly to pathophysiology across cardiovascular disease, cancer biology, inflammatory disorders, neurodegeneration/metabolic syndrome. Because this term does not specify one molecular target but rather encompasses several interrelated proteins/pathways/processes central to human health/disease—and because no single canonical abbreviation exists—this entry should be considered non-specific/incomplete when seeking structured information about drug targets.

Other names

PUFA metabolismPolyunsaturated fatty acid biosynthesisFatty acid desaturation/elongation pathway

Drugs/nutrients that modulate this process act by: - Inhibiting or enhancing activity/expression of key metabolic enzymes (desaturases/elognases/synthases) - Altering substrate availability for PUFA synthesis/breakdown. - Modulating downstream signaling via lipid mediators derived from PUFAs.